Mr. Donald McCaffrey reports
RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2023 MEETING OF SHAREHOLDERS
Resverlogix Corp. has held its annual meeting of shareholders in Calgary, Alta.
During business proceedings at the meeting, shareholders elected five board members until the next annual meeting. The voting results of shares represented at the meeting for individual directors are set out in the attached table.
Votes for Votes withheld Per cent for Per cent withheld
Donald J. McCaffrey 122,884,287 11,547,550 91.41% 8.59%
Shawn Lu 123,340,266 11,091,571 91.75% 8.25%
Kelly McNeill 127,204,762 7,227,075 94.62% 5.38%
Siu Lun (Dicky) To 127,856,904 6,574,933 95.11% 4.89%
Kenneth Zuerblis 129,096,743 5,335,094 96.03% 3.97%
Resverlogix shareholders approved all resolutions outlined in the notice of meeting and management information circular dated May 10, 2023. The information circular is available on SEDAR and on the Resverlogix website.
A webcast archive of the executive presentation portion of the meeting will be available.
About Resverlogix Corp.
Founded in 2001, Resverlogix is a Calgary-based, late-stage, biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Its new class of epigenetic therapies are designed to regulate the expression of disease-causing genes. It aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.
The company's clinical program is focused on evaluating its lead candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions.
Resverlogix common shares trade on the Toronto Stock Exchange (RVX).
© 2025 Canjex Publishing Ltd. All rights reserved.